Order Article Reprints

Mendes B, Figueiredo C, Cabral M, Borba A, Mineiro A, Cardoso J, Calvinho P, Semedo L, Fragata J. Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review. Transplantology. 2022; 3(3):267-274. https://doi.org/10.3390/transplantology3030027

Mendes, Bruno, Carlos Figueiredo, Mariana Cabral, Alexandra Borba, Alexandra Mineiro, João Cardoso, Paulo Calvinho, Luísa Semedo, and José Fragata. 2022. "Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review" Transplantology 3, no. 3: 267-274. https://doi.org/10.3390/transplantology3030027

Mendes, B., Figueiredo, C., Cabral, M., Borba, A., Mineiro, A., Cardoso, J., Calvinho, P., Semedo, L., & Fragata, J. (2022). Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review. Transplantology, 3(3), 267-274. https://doi.org/10.3390/transplantology3030027